NPIPB7

Across TCGA pan-cancer cohorts, NPIPB7 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated NPIPB7 data layer compared with 2 for mutation status.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher NPIPB7 RNA is associated with better overall survival. In most high-consensus cancer types, elevated NPIPB7 expression acts as an unfavorable survival marker, although some lineages such as SKCM and ACC show a favorable association.

SKCM, ACC, and KIRC are the cancer types where NPIPB7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	IV	0.867	0.225	.001	45	view →
ACC	DFS	Tertile	All	0.923	0.543	.002	39	view →
KIRC	DFS	Tertile	IV	0.175	0.499	.003	38	view →
LUAD	DFS	Median	III,IV	0.447	0.189	.007	35	view →
UCS	DFS	Median	II,III,IV	0.428	0.196	.013	26	view →
CESC	DFS	Median	II,III,IV	0.684	0.857	.002	26	view →
BRCA	DFS	Median	IV	0.317	0.711	.003	21	view →
PRAD	OS	Median	All	0.973	1.000	.003	20	view →
CHOL	DFS	Median	All	0.110	0.691	<.001	18	view →
LUSC	OS	Tertile	IV	0.001	0.651	.025	18	view →
KICH	DFS	Tertile	All	0.786	1.000	.006	15	view →
SARC	OS	Tertile	All	0.901	0.681	.004	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

NPIPB7–SKCM (OS)

Open the SKCM breakdown →